Tesamorelin: Research Applications

💊 HIV-Associated Lipodystrophy (FDA-registered)

O(a) principal clinical application. Two pivotal Phase 3 trials (n=816) demonstrated 14–18% VAT reduction with 2 mg SC daily, with improvements in triglycerides (-12.3%), body image, and waist circumference. Reductions were manteve over 52 weeks but reversed upon discontinuation. [4] [10]

🫁 NAFLD / NASH

A 12-month RCT (n=61) in HIV-infected sujeitos de estudo showed 37% hepatico(a) fat reduction, with 35% achieving normal hepatico(a) fat fraction (<5%). Criticamente, Tesamorelin preveniu progression of liver fibrose (10.5% vs 37.5% in placebo, P=0.04). [11]

🧠 Cognitivo Function / MCI

In a blinded RCT (n=152) of healthy older adults and MCI sujeitos de estudo, 1 mg diariamente por 20 weeks melhorou executive function (P=0.005) and global cognition (P=0.03), with IGF-1 increasing +117%. Mechanisms involve aumentou GABA and amyloid-beta modulacao. [13]

🦴 Peripheral Nerve Regeneration

Preclinical GH models showed aprimorou median regeneracao nervosa (axon density P<0.005, myelin thickness P<0.0001) and melhorou muscle re-innervation (38% vs 27.9%, P<0.02). Tesamorelin is identificado(a) como the optimal agent for human traducao. [14]

❤️ Cardiovascular Risk Reduction

Reduces triglycerides and melhora carotid intima-media thickness (cIMT). VAT reduction is theorized to lower atherosclerotic doenca risco cardiovascular. Long-term desfechos cardiovasculares remain under study. [15]

💪 Sarcopenia / Muscle Quality

Increases musculo esqueletico density and area (particularmente trunk region), independente de changes in muscle mass quantity. Replaces hypertrophic lipid-engorged fat cells with healthy tissue. [12]

🍬 Metabolic Syndrome / Type 2 Diabetes

A tolerability study in T2D sujeitos de estudo (n=53) demonstrated neutral glucose effects — no significant changes in fasting glucose, HbA1c, or insulin response vs placebo. No entanto, Phase 3 HIV data showed aumentou HbA1c risk (HR 3.3 vs placebo), warranting monitoring. [16]